1-19 of 19
Yves Pommier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial

Melissa L. Abel, Nobuyuki Takahashi, Cody Peer, Christophe E. Redon, Samantha Nichols, Rasa Vilimas, Min-Jung Lee, Sunmin Lee, Meenakshi Shelat, Robbie Kattappuram, Linda Sciuto, Danielle Pinkiert, Chante Graham, Donna Butcher, Baktiar Karim, Ajit Kumar Sharma, Justin Malin, Rajesh Kumar, Christopher W. Schultz, Shubhank Goyal, Jaydira del Rivero, Manan Krishnamurthy, Deep Upadhyay, Brett Schroeder, Tristan Sissung, Manoj Tyagi, Jung Kim, Yves Pommier, Mirit Aladjem, Mark Raffeld, William Douglas Figg, Jane Trepel, Liqiang Xi, Parth Desai, Anish Thomas
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3603–3611.
https://doi.org/10.1158/1078-0432.CCR-23-0536
Published: 15 September 2023
View article titled, Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Open the PDF for Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial in another window
Includes: Supplementary data
Journal Articles

New Life of Topoisomerase I Inhibitors as Antibody–Drug Conjugate Warheads

Yves Pommier, Anish Thomas
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 991–993.
https://doi.org/10.1158/1078-0432.CCR-22-3640
Published: 14 March 2023
View article titled, New Life of Topoisomerase I Inhibitors as Antibody–Drug Conjugate Warheads
Open the PDF for New Life of Topoisomerase I Inhibitors as Antibody–Drug Conjugate Warheads in another window
Journal Articles

Abstract NT-110: EFFICACY OF NOVEL TOPOISOMERASE 1 INHIBITORS AND THEIR SYNERGY WITH PARP INHIBITORS IN A MURINE MODEL FOR OVARIAN CANCER

Ludmila Szabova, Melanie Gordon, Laetitia Matzi, Yves Pommier, Zoe Weaver Ohler
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): NT-110.
https://doi.org/10.1158/1557-3265.OVCASYMP18-NT-110
Published: 15 November 2019
View article titled, Abstract NT-110: EFFICACY OF NOVEL TOPOISOMERASE 1 INHIBITORS AND THEIR SYNERGY WITH PARP INHIBITORS IN A MURINE MODEL FOR OVARIAN CANCER
Journal Articles

Targeting Topoisomerase I in the Era of Precision Medicine

Anish Thomas, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6581–6589.
https://doi.org/10.1158/1078-0432.CCR-19-1089
Published: 15 November 2019
View article titled, Targeting Topoisomerase I in the Era of Precision Medicine
Open the PDF for Targeting Topoisomerase I in the Era of Precision Medicine in another window
Includes: Supplementary data
Journal Articles

The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib

Laetitia Marzi, Ludmila Szabova, Melanie Gordon, Zoe Weaver Ohler, Shyam K. Sharan, Michael L. Beshiri, Moudjib Etemadi, Junko Murai, Kathleen Kelly, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6206–6216.
https://doi.org/10.1158/1078-0432.CCR-19-0419
Published: 15 October 2019
View article titled, The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Open the PDF for The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib in another window
Includes: Supplementary data
Journal Articles

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma

Jenna H. Burton, Christina Mazcko, Amy LeBlanc, Joseph M. Covey, Jiuping Ji, Robert J. Kinders, Ralph E. Parchment, Chand Khanna, Melissa Paoloni, Sue Lana, Kristen Weishaar, Cheryl London, William Kisseberth, Erika Krick, David Vail, Michael Childress, Jeffrey N. Bryan, Lisa Barber, E.J. Ehrhart, Michael Kent, Timothy Fan, Kelvin Kow, Nicole Northup, Heather Wilson-Robles, Joseph Tomaszewski, Julianne L. Holleran, Miguel Muzzio, Julie Eiseman, Jan H. Beumer, James H. Doroshow, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5830–5840.
https://doi.org/10.1158/1078-0432.CCR-18-1498
Published: 03 December 2018
View article titled, NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma
Open the PDF for NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma in another window
Includes: Supplementary data
Journal Articles

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors

Sai-Wen Tang, Anish Thomas, Junko Murai, Jane B. Trepel, Susan E. Bates, Vinodh N. Rajapakse, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1944–1953.
https://doi.org/10.1158/1078-0432.CCR-17-0443
Published: 12 April 2018
View article titled, Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (<em>SLFN11)</em> Expression with Class I Histone Deacetylase Inhibitors
Open the PDF for Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (<em>SLFN11)</em> Expression with Class I Histone Deacetylase Inhibitors in another window
Includes: Supplementary data
Journal Articles

Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer

Hamza Mameri, Ivan Bièche, Didier Meseure, Elisabetta Marangoni, Géraldine Buhagiar-Labarchède, André Nicolas, Sophie Vacher, Rosine Onclercq-Delic, Vinodh Rajapakse, Sudhir Varma, William C. Reinhold, Yves Pommier, Mounira Amor-Guéret
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (8): 2116–2126.
https://doi.org/10.1158/1078-0432.CCR-16-0626
Published: 13 April 2017
View article titled, Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer
Open the PDF for Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer in another window
Includes: Supplementary data
Journal Articles

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors

Wael Jdey, Sylvain Thierry, Christophe Russo, Flavien Devun, Muthana Al Abo, Patricia Noguiez-Hellin, Jian-Sheng Sun, Emmanuel Barillot, Andrei Zinovyev, Inna Kuperstein, Yves Pommier, Marie Dutreix
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (4): 1001–1011.
https://doi.org/10.1158/1078-0432.CCR-16-1193
Published: 14 February 2017
View article titled, Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors
Open the PDF for Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors in another window
Includes: Supplementary data
Journal Articles

SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma

Sai-Wen Tang, Sven Bilke, Liang Cao, Junko Murai, Fabricio G. Sousa, Mihoko Yamade, Vinodh Rajapakse, Sudhir Varma, Lee J. Helman, Javed Khan, Paul S. Meltzer, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (18): 4184–4193.
https://doi.org/10.1158/1078-0432.CCR-14-2112
Published: 14 September 2015
View article titled, <em>SLFN11</em> Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma
Open the PDF for <em>SLFN11</em> Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma in another window
Includes: Supplementary data
Journal Articles

Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60

William C. Reinhold, Margot Sunshine, Sudhir Varma, James H. Doroshow, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17): 3841–3852.
https://doi.org/10.1158/1078-0432.CCR-15-0335
Published: 31 August 2015
View article titled, Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60
Open the PDF for Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60 in another window
Includes: Supplementary data
Journal Articles

Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity

Salim Khiati, Ilaria Dalla Rosa, Carole Sourbier, Xuefei Ma, V. Ashutosh Rao, Leonard M. Neckers, Hongliang Zhang, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (18): 4873–4881.
https://doi.org/10.1158/1078-0432.CCR-13-3373
Published: 14 September 2014
View article titled, Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity
Open the PDF for Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity in another window
Includes: Supplementary data
Journal Articles

Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth

Patrick J. Grohar, Laure E. Segars, Choh Yeung, Yves Pommier, Maurizio D'Incalci, Arnulfo Mendoza, Lee J. Helman
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (5): 1190–1203.
https://doi.org/10.1158/1078-0432.CCR-13-0901
Published: 02 March 2014
View article titled, Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth
Open the PDF for Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth in another window
Includes: Supplementary data
Journal Articles

Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity

Robert J. Kinders, Melinda Hollingshead, Scott Lawrence, Jiuping Ji, Brian Tabb, William M. Bonner, Yves Pommier, Larry Rubinstein, Yvonne A. Evrard, Ralph E. Parchment, Joseph Tomaszewski, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (22): 5447–5457.
https://doi.org/10.1158/1078-0432.CCR-09-3076
Published: 14 November 2010
View article titled, Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity
Open the PDF for Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity in another window
Includes: Supplementary data
Journal Articles

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

Christophe E. Redon, Asako J. Nakamura, Yong-Wei Zhang, Jiuping (Jay) Ji, William M. Bonner, Robert J. Kinders, Ralph E. Parchment, James H. Doroshow, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (18): 4532–4542.
https://doi.org/10.1158/1078-0432.CCR-10-0523
Published: 14 September 2010
View article titled, Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
Open the PDF for Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers in another window
Journal Articles

Von Hippel-Lindau–Coupled and Transcription-Coupled Nucleotide Excision Repair–Dependent Degradation of RNA Polymerase II in Response to Trabectedin

Gregory J. Aune, Kazutaka Takagi, Olivier Sordet, Josée Guirouilh-Barbat, Smitha Antony, Vilhelm A. Bohr, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6449–6455.
https://doi.org/10.1158/1078-0432.CCR-08-0730
Published: 16 October 2008
View article titled, Von Hippel-Lindau–Coupled and Transcription-Coupled Nucleotide Excision Repair–Dependent Degradation of RNA Polymerase II in Response to Trabectedin
Open the PDF for Von Hippel-Lindau–Coupled and Transcription-Coupled Nucleotide Excision Repair–Dependent Degradation of RNA Polymerase II in Response to Trabectedin in another window
Journal Articles

Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors

Yves Pommier, John N. Weinstein, Mirit I. Aladjem, Kurt W. Kohn
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (9): 2657–2661.
https://doi.org/10.1158/1078-0432.CCR-06-0743
Published: 04 May 2006
View article titled, Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors
Open the PDF for Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors in another window
Includes: Supplementary data
Journal Articles

Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine), an Antimetabolite That Poisons Topoisomerase I

Philippe Pourquier, Christopher Gioffre, Glenda Kohlhagen, Yoshimasa Urasaki, François Goldwasser, Lary W. Hertel, Shuyuan Yu, Richard T. Pon, William H. Gmeiner, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (8): 2499–2504.
Published: 01 August 2002
View article titled, Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine), an Antimetabolite That Poisons Topoisomerase I
Open the PDF for Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine), an Antimetabolite That Poisons Topoisomerase I in another window
Journal Articles

Ecteinascidin 743 Induces Protein-linked DNA Breaks in Human Colon Carcinoma HCT116 Cells and Is Cytotoxic Independently of Topoisomerase I Expression

Yuji Takebayashi, François Goldwasser, Yoshimasa Urasaki, Glenda Kohlhagen, Yves Pommier
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (1): 185–191.
Published: 01 January 2001
View article titled, Ecteinascidin 743 Induces Protein-linked DNA Breaks in Human Colon Carcinoma HCT116 Cells and Is Cytotoxic Independently of Topoisomerase I Expression
Open the PDF for Ecteinascidin 743 Induces Protein-linked DNA Breaks in Human Colon Carcinoma HCT116 Cells and Is Cytotoxic Independently of Topoisomerase I Expression in another window